Name | Number of supported studies | Average coverage | |
---|---|---|---|
regulatory T cell | 19 studies | 27% ± 10% | |
CD4-positive, alpha-beta T cell | 9 studies | 18% ± 2% | |
mucosal invariant T cell | 6 studies | 19% ± 3% | |
T cell | 4 studies | 22% ± 6% | |
T-helper 17 cell | 4 studies | 17% ± 1% | |
plasma cell | 3 studies | 24% ± 5% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 16% ± 1% | |
effector CD4-positive, alpha-beta T cell | 3 studies | 27% ± 8% | |
CD4-positive, alpha-beta cytotoxic T cell | 3 studies | 28% ± 10% | |
CD4-positive, alpha-beta memory T cell | 3 studies | 31% ± 8% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% |
Insufficient scRNA-seq data for expression of SLAMF1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 330.97 | 574 / 578 | 84% | 3.38 | 969 / 1155 |
stomach | 89% | 138.92 | 319 / 359 | 73% | 2.23 | 208 / 286 |
bladder | 95% | 174.29 | 20 / 21 | 53% | 1.97 | 265 / 504 |
breast | 76% | 102.97 | 351 / 459 | 64% | 2.72 | 712 / 1118 |
intestine | 76% | 293.93 | 734 / 966 | 63% | 1.89 | 334 / 527 |
kidney | 78% | 166.65 | 69 / 89 | 57% | 1.50 | 510 / 901 |
thymus | 80% | 131.57 | 522 / 653 | 53% | 12.07 | 321 / 605 |
esophagus | 59% | 67.67 | 846 / 1445 | 56% | 1.56 | 103 / 183 |
prostate | 73% | 94.24 | 180 / 245 | 39% | 0.85 | 197 / 502 |
skin | 51% | 50.98 | 928 / 1809 | 61% | 8.43 | 288 / 472 |
pancreas | 37% | 26.88 | 120 / 328 | 66% | 2.75 | 117 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 44.91 | 29 / 29 |
spleen | 100% | 882.70 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 4523.43 | 918 / 929 | 0% | 0 | 0 / 0 |
uterus | 39% | 23.40 | 67 / 170 | 54% | 1.69 | 248 / 459 |
adipose | 91% | 155.90 | 1098 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 5.41 | 39 / 45 |
liver | 49% | 30.94 | 111 / 226 | 34% | 0.85 | 140 / 406 |
heart | 43% | 70.35 | 368 / 861 | 0% | 0 | 0 / 0 |
ovary | 14% | 9.31 | 26 / 180 | 24% | 0.46 | 103 / 430 |
blood vessel | 36% | 40.25 | 487 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 16% | 15.74 | 42 / 258 | 5% | 0.06 | 11 / 230 |
eye | 0% | 0 | 0 / 0 | 13% | 0.38 | 10 / 80 |
muscle | 12% | 23.08 | 95 / 803 | 0% | 0 | 0 / 0 |
brain | 2% | 1.18 | 56 / 2642 | 4% | 0.15 | 30 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2000349 | Biological process | negative regulation of CD40 signaling pathway |
GO_0002277 | Biological process | myeloid dendritic cell activation involved in immune response |
GO_0042104 | Biological process | positive regulation of activated T cell proliferation |
GO_2000556 | Biological process | positive regulation of T-helper 1 cell cytokine production |
GO_0002725 | Biological process | negative regulation of T cell cytokine production |
GO_0031338 | Biological process | regulation of vesicle fusion |
GO_0001779 | Biological process | natural killer cell differentiation |
GO_0032715 | Biological process | negative regulation of interleukin-6 production |
GO_0045087 | Biological process | innate immune response |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0032695 | Biological process | negative regulation of interleukin-12 production |
GO_0007155 | Biological process | cell adhesion |
GO_0010759 | Biological process | positive regulation of macrophage chemotaxis |
GO_0002250 | Biological process | adaptive immune response |
GO_2000510 | Biological process | positive regulation of dendritic cell chemotaxis |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0001787 | Biological process | natural killer cell proliferation |
GO_0006909 | Biological process | phagocytosis |
GO_0032689 | Biological process | negative regulation of type II interferon production |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0002232 | Biological process | leukocyte chemotaxis involved in inflammatory response |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0045335 | Cellular component | phagocytic vesicle |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0001618 | Molecular function | virus receptor activity |
GO_0042169 | Molecular function | SH2 domain binding |
GO_0098631 | Molecular function | cell adhesion mediator activity |
GO_0003823 | Molecular function | antigen binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SLAMF1 |
Protein name | Signaling lymphocytic activation molecule (CDw150) (IPO-3) (SLAM family member 1) (CD antigen CD150) |
Synonyms | SLAM |
Description | FUNCTION: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. SLAMF1-induced signal-transduction events in T-lymphocytes are different from those in B-cells. Two modes of SLAMF1 signaling seem to exist: one depending on SH2D1A (and perhaps SH2D1B) and another in which protein-tyrosine phosphatase 2C (PTPN11)-dependent signal transduction operates. Initially it has been proposed that association with SH2D1A prevents binding to inhibitory effectors including INPP5D/SHIP1 and PTPN11/SHP-2 . However, signaling is also regulated by SH2D1A which can simultaneously interact with and recruit FYN which subsequently phosphorylates and activates SLAMF1 . Mediates IL-2-independent proliferation of activated T-cells during immune responses and induces IFN-gamma production (By similarity). Downstreaming signaling involves INPP5D, DOK1 and DOK2 leading to inhibited IFN-gamma production in T-cells, and PRKCQ, BCL10 and NFKB1 leading to increased T-cell activation and Th2 cytokine production (By similarity). Promotes T-cell receptor-induced IL-4 secretion by CD4(+) cells (By similarity). Inhibits antigen receptor-mediated production of IFN-gamma, but not IL-2, in CD4(-)/CD8(-) T-cells (By similarity). Required for IL-4 production by germinal centers T follicular helper (T(Fh))cells (By similarity). May inhibit CD40-induced signal transduction in monocyte-derived dendritic cells . May play a role in allergic responses and may regulate allergen-induced Th2 cytokine and Th1 cytokine secretion (By similarity). In conjunction with SLAMF6 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage. Involved in the peripheral differentiation of indifferent natural killer T (iNKT) cells toward a regulatory NKT2 type (By similarity). In macrophages involved in down-regulation of IL-12, TNF-alpha and nitric oxide in response to lipopolysaccharide (LPS) (By similarity). In B-cells activates the ERK signaling pathway independently of SH2D1A but implicating both, SYK and INPP5D, and activates Akt signaling dependent on SYK and SH2D1A (By similarity). In B-cells also activates p38 MAPK and JNK1 and JNK2 . In conjunction with CD84/SLAMF5 and SLAMF6 may be a negative regulator of the humoral immune response (By similarity). Involved in innate immune response against Gram-negative bacteria in macrophages; probably recognizes OmpC and/or OmpF on the bacterial surface, regulates phagosome maturation and recruitment of the PI3K complex II (PI3KC3-C2) leading to accumulation of PdtIns(3)P and NOX2 activity in the phagosomes . .; FUNCTION: (Microbial infection) Acts as a receptor for Measles virus; also including isoform 4. . |
Accessions | ENST00000538290.2 [Q13291-4] Q13291 ENST00000302035.11 [Q13291-1] |